Bionano Genomics, Inc. (BNGO) stock
Close on Nov 17, 2026Market cap $11.21MP/E –Yield –
Earnings
Bionano Genomics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Bionano Genomics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 22, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026after the close | $8.30M | +12.2% | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026during market hours | $8.20M | +22.4% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026during market hours | $6.70M | +3.1% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 23, 2026during market hours | $8.00M | -2.4% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025during market hours | $7.40M | +21.3% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025during market hours | $6.70M | -14.1% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025during market hours | $6.50M | -26.1% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025during market hours | $8.20M | -23.4% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024during market hours | $6.10M | -34.4% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024during market hours | $7.80M | -10.3% | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | $8.80M | +18.9% | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 5, 2024during market hours | $10.70M | +30.5% | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023during market hours | $9.30M | +29.2% | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023during market hours | $8.70M | +29.9% | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $7.40M | +29.8% | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023during market hours | $8.20M | +30.2% | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | $7.20M | +53.2% | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $6.70M | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | $5.70M | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022during market hours | $6.30M | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $4.70M | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 23, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 15, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Bionano Genomics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue guidance | FY2026 | $31.00M – $33.00M | $30.00M – $33.00M | Raised | Nov 10, 2026 |
| revenue guidance | FY2026 | $31.00M – $33.00M | $30.00M – $33.00M | Raised | Aug 10, 2026 |
Guidance vs results
The last range Bionano Genomics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $8.20M – $8.60M | $8.30M | Within range |
| Q2 FY2026 | Revenue | $7.50M – $7.80M | $8.20M | Above range |
| Q1 FY2026 | Revenue | $6.50M – $6.70M | $6.70M | Within range |
| FY2025 | Revenue | $26.00M – $30.00M | $28.60MΣ4Q | Within range |
| Q4 FY2025 | Revenue | $7.50M – $7.90M | $8.00M | Above range |
| Q3 FY2025 | Revenue | $6.70M – $7.20M | $7.40M | Above range |
| Q2 FY2025 | Revenue | $6.30M – $6.80M | $6.70M | Within range |
| Q1 FY2025 | Revenue | $6.20M – $6.30M | $6.50M | Above range |
| Q3 FY2024 | Revenue | $6.50M – $6.80M | $6.10M | Below range |
| Q2 FY2024 | Revenue | $7.80M – $8.20M | $7.80M | Within range |
| Q1 FY2024 | Revenue | $8.25M – $8.75M | $8.80M | Above range |
| Q4 FY2022 | Revenue | $8.10M – $8.40M | $8.20M | Within range |
| Q4 FY2021 | Revenue | $5.80M – $6.20M | $6.30M | Above range |
Guidance history
Every forecast Bionano Genomics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2026 | revenue guidance | FY2026 | $31.00M – $33.00M | Raised |
| Aug 10, 2026 | revenue guidance | FY2026 | $31.00M – $33.00M | Raised |
| Aug 10, 2026 | revenue guidance | Q3 FY2026 | $8.20M – $8.60M | New |
| May 13, 2026 | revenue guidance | FY2026 | $30.00M – $33.00M | New |
| May 13, 2026 | revenue guidance | Q2 FY2026 | $7.50M – $7.80M | New |
| Mar 23, 2026 | revenue | Q1 FY2026 | $6.50M – $6.70M | New |
| Mar 23, 2026 | revenue | FY2026 | $30.00M – $33.00M | New |
| Nov 13, 2025 | new OGM system installations | FY2025 | 25 | New |
| Nov 13, 2025 | revenue | FY2025 | $26.00M – $30.00M | New |
| Nov 13, 2025 | revenue | Q4 FY2025 | $7.50M – $7.90M | New |
| Aug 14, 2025 | new OGM installation expectations | FY2025 | 20 – 25 | Raised |
| Aug 14, 2025 | revenue | Q3 FY2025 | $6.70M – $7.20M | New |
| Aug 14, 2025 | revenue | FY2025 | $26.00M – $30.00M | Reaffirmed |
| May 14, 2025 | installation of new OGM systems | FY2025 | 15 – 20 | Reaffirmed |
| May 14, 2025 | revenue | Q2 FY2025 | $6.30M – $6.80M | New |
| May 14, 2025 | revenue | FY2025 | $26.00M – $30.00M | Lowered |
| Mar 31, 2025 | Installation of new OGM systems | FY2025 | 15 – 20 | New |
| Mar 31, 2025 | revenue | Q1 FY2025 | $6.20M – $6.30M | New |
| Mar 31, 2025 | revenue | FY2025 | $29.00M – $32.00M | New |
| Oct 10, 2024 | revenue | Q3 FY2024 | $6.50M – $6.80M | Lowered |
| Aug 7, 2024 | revenue | Q3 FY2024 | $7.90M – $8.90M | New |
| Aug 7, 2024 | revenue | FY2024 | $36.00M – $40.00M | Lowered |
| May 8, 2024 | revenue | Q2 FY2024 | $7.80M – $8.20M | New |
| May 8, 2024 | revenue guidance | FY2024 | $37.00M – $41.00M | Reaffirmed |
| Mar 5, 2024 | installation of new OGM systems | FY2024 | 80 – 100 | New |
| Mar 5, 2024 | installed base | FY2024 | 381 – 401 | Raised |
| Mar 5, 2024 | revenue | Q1 FY2024 | $8.25M – $8.75M | New |
| Mar 5, 2024 | revenue | FY2024 | $37.00M – $41.00M | New |
| Nov 8, 2023 | revenue | FY2023 | $35.00M – $38.00M | Reaffirmed |
| Apr 24, 2023 | installed base | FY2023 | 325 | Reaffirmed |
| Apr 24, 2023 | revenue | FY2023 | $35.00M – $38.00M | Reaffirmed |
| Mar 9, 2023 | installed base of OGM systems | FY2023 | 325 | New |
| Mar 9, 2023 | revenue | FY2023 | $35.00M – $38.00M | New |
| Jan 5, 2023 | Revenues | Q4 FY2022 | $8.10M – $8.40M | Raised |
| Jan 5, 2023 | Full year 2022 revenue | FY2022 | $27.70M – $28.00M | Raised |
| Nov 3, 2022 | revenues | Q4 FY2022 | $7.50M – $8.00M | New |
| Aug 4, 2022 | revenue guidance | FY2022 | $24.00M – $27.00M | Reaffirmed |
| May 5, 2022 | revenue | FY2022 | $24.00M – $27.00M | Reaffirmed |
| Mar 1, 2022 | revenue | FY2022 | $24.00M – $27.00M | New |
| Jan 12, 2022 | revenue | Q4 FY2021 | $5.80M – $6.20M | New |
| Jan 12, 2022 | revenue | FY2021 | $17.50M – $17.90M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Bionano Genomics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- News
- Results
- News
- Results
- Results
- Results
- News
- News
- Results
- Results
- Results
See a number that looks wrong?